Volume 32, Issue 10 (January 2022)                   Studies in Medical Sciences 2022, 32(10): 782-792 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharififar S, Dadashi A, Orandi A, Shiri Malekabad E, Khorramnia S, Alazmani Noodeh F. EFFICACY AND SAFETY OF FAVIPIRAVIR IN PATIENTS WITH COVID-19: A REVIEW OF SYSTEMATIC REVIEWS AND META-ANALYSIS. Studies in Medical Sciences 2022; 32 (10) :782-792
URL: http://umj.umsu.ac.ir/article-1-5679-en.html
MSc of Epidemiology, AJA University of Medical Sciences, Tehran, Iran (Corresponding Author) , ebad.shiri1986@gmail.com
Abstract:   (2195 Views)
Background &  Aims: Favipiravir is an antiviral drug that is widely used in patients with Covid-19. The aim of this study was to review the systematic review and meta-analysis studies of Favipiravir in patients with Covid-19.
Materials & Methods: An electronic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science databases until December 2021. In addition, other databases were searched. A manual search of studies and other sources was also conducted to find evidence. The Overview Quality Assessment Questionnaire tool was used to evaluate the quality of articles.
Results: Seven systematic review and meta-analysis studies were included in the study. The results showed that there was no statistically significant difference in mortality between Favipiravir and control groups in the patients with Covid-19. Other findings showed that the rate of clinical improvement was higher in two studies on day 7 in the Favipiravir group than that in the control group, while in another study, no statistically significant difference was found between Favipiravir and the control groups. Other findings of the study showed that negative RT-PCR result rate in four studies in the Favipiravir group was higher than that in the control group, although in one study no statistically significant difference was found between the two groups. Also, no difference in mechanical ventilation was found in the favipiravir and control groups. Regarding Side effects, most studies indicated that there was no difference between Favipiravir and control.
Conclusion: The results showed that Favipiravir has no effect on mortality and mechanical ventilation and only affects the rate of clinical improvement of patients and negative result for RT-PCR.
Full-Text [PDF 525 kb]   (365 Downloads)    
Type of Study: Review article | Subject: عفونی

1. Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab 2020;2(7):572-85. [DOI:10.1038/s42255-020-0237-2] [PMID] [PMCID]
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
3. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92(4):401. [DOI:10.1002/jmv.25678] [PMID] [PMCID]
4. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145(6). [DOI:10.1542/peds.2020-0702] [PMID]
5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. [DOI:10.1016/j.jaut.2020.102433] [PMID] [PMCID]
6. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 2020;20(7):773. [DOI:10.1016/S1473-3099(20)30195-X]
7. Dil S, Dil N, Maken ZH. COVID-19 trends and forecast in the Eastern Mediterranean Region with a Particular Focus on Pakistan. Cureus 2020;12(6). [DOI:10.7759/cureus.8582] [PMID] [PMCID]
8. Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls 2021. [URL]
9. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514-23. [DOI:10.1016/S0140-6736(20)30154-9]
10. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med 2020;23(4):268-71. [DOI:10.34172/aim.2020.09] [PMID]
11. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115(10). [DOI:10.14309/ajg.0000000000000620] [PMID] [PMCID]
12. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5(7):802-10. [DOI:10.1001/jamacardio.2020.0950] [PMID] [PMCID]
13. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica 2020;44:e40. [DOI:10.26633/RPSP.2020.40] [PMID] [PMCID]
14. Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis. DARU J Pharm Sci 2020:1-13. [DOI:10.1007/s40199-020-00367-4] [PMID] [PMCID]
15. Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals. 2020;13(5):96. [DOI:10.3390/ph13050096] [PMID] [PMCID]
16. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic? J Virus Erad 2020;6(2):45-51. [DOI:10.1016/S2055-6640(20)30016-9]
17. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54. [DOI:10.1016/j.antiviral.2013.09.015] [PMID] [PMCID]
18. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14(1):58-60. [DOI:10.5582/ddt.2020.01012] [PMID]
19. Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, et al. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 2018;15(3):e1002535. [DOI:10.1371/journal.pmed.1002535] [PMID] [PMCID]
20. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res 2021;71(03):166-70. [DOI:10.1055/a-1296-7935] [PMID] [PMCID]
21. Goldhill DH, Te Velthuis AJ, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci 2018;115(45):11613-8. [DOI:10.1073/pnas.1811345115] [PMID] [PMCID]
22. Singh AK, Singh A, Singh R, Misra A. Hydroxychloroquine in patients with COVID-19: A systematic Review and meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020;14(4):589-96. [DOI:10.1016/j.dsx.2020.05.017] [PMID] [PMCID]
23. Amani B, Khanijahani A, Amani B. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. Sci Rep 2021;11(1):1-10. [DOI:10.1038/s41598-021-91089-3] [PMID] [PMCID]
24. Amani B, Amani B, Zareei S, Zareei M. Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis. Immun Inflamm Dis 2021;9(4):1197-208. [DOI:10.1002/iid3.502] [PMID] [PMCID]
25. Lan S-H, Lai C-C, Huang H-T, Chang S-P, Lu L-C, Hsueh P-R. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents 2020;56(3):106103. [DOI:10.1016/j.ijantimicag.2020.106103] [PMID] [PMCID]
26. Amani B, Khanijahani A, Amani B, Hashemi P. Lopinavir/Ritonavir for COVID-19: a systematic Review and Meta-Analysis. Int J Pharm Pharm Sci 2021;24:246-57. [DOI:10.18433/jpps31668] [PMID]
27. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991;44(11):1271-8. [DOI:10.1016/0895-4356(91)90160-B]
28. Ghula S, Aziz JA, Makram AM, Tawfik GM, Abozaid AA-F, Pancharatnam RA, et al. The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies. 2021. [Google Scholar]
29. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. Sci Rep 2021;11(1):1-11. [DOI:10.1038/s41598-021-90551-6] [PMID] [PMCID]
30. Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):1-13. [DOI:10.1186/s12879-021-06164-x] [PMID] [PMCID]
31. Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek İB, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis 2021;40(12):2575-83. [DOI:10.1007/s10096-021-04307-1] [PMID] [PMCID]
32. Prakash A, Singh H, Kaur H, Semwal A, Sarma P, Bhattacharyya A, et al. systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol 2020;52(5):414-21. [DOI:10.4103/ijp.ijp_998_20] [PMID] [PMCID]
33. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J 2020;17(1):1-15. [DOI:10.1186/s12985-020-01412-z] [PMID] [PMCID]
34. Wei FF, Moradkhani A, Hemmati Hezaveh H, Miraboutalebi SA, Salehi L. Evaluating the treatment with favipiravir in patients infected by COVID-19: a systematic review and meta-analysis. J Int Dent Med Res 2020;2(3):87-91.
35. Bown M, Sutton A. Quality control in systematic reviews and meta-analyses. EJVES. 2010;40(5):669-77. https://doi.org/10.1016/j.jvs.2010.09.037 [DOI:10.1016/j.ejvs.2010.07.011]
36. Ioannidis JP, Haidich A-B, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286(7):821-30. [DOI:10.1001/jama.286.7.821] [PMID]
37. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? NEJM. 2000;342(25):1907-9. [DOI:10.1056/NEJM200006223422511] [PMID]
38. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014(4). [DOI:10.1002/14651858.MR000034.pub2] [PMID] [PMCID]
39. Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, et al. Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med 2021;19(1):1-15. [DOI:10.1186/s12916-021-02176-1] [PMID] [PMCID]
40. Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. Br Med J 2000;321(7256):255-6. [DOI:10.1136/bmj.321.7256.255] [PMID] [PMCID]
41. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2019. [DOI:10.1002/9781119536604]
42. Bazelier MT, Eriksson I, de Vries F, Schmidt MK, Raitanen J, Haukka J, et al. Data management and data analysis techniques in pharmacoepidemiological studies using a pre‐planned multi‐database approach: a systematic literature review. Pharmacoepidemiol Drug Saf 2015;24(9):897-905. [DOI:10.1002/pds.3828] [PMID] [PMCID]
43. Useem J, Brennan A, LaValley M, Vickery M, Ameli O, Reinen N, et al. systematic differences between Cochrane and non-Cochrane meta-analyses on the same topic: a matched pair analysis. PLoS One 2015;10(12):e0144980. [DOI:10.1371/journal.pone.0144980] [PMID] [PMCID]
44. Marshall IJ, Marshall R, Wallace BC, Brassey J, Thomas J. Rapid reviews may produce different results to systematic reviews: a meta-epidemiological study. J Clin Epidemiol 2019;109:30-41. [DOI:10.1016/j.jclinepi.2018.12.015] [PMID] [PMCID]
45. Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel 2013;5(4):219. [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb